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Electroconvulsive therapy (ECT) employs the elective induction of generalizes seizures as
a potent treatment for severe psychiatric illness. As such, ECT provides an opportunity
to rigorously study the recovery of consciousness, reconstitution of cognition, and
electroencephalographic (EEG) activity following seizures. Fifteen patients with major
depressive disorder refractory to pharmacologic therapy will be enrolled (Clinicaltrials.gov,
NCT02761330). Adequate seizure duration will be confirmed following right unilateral
ECT under etomidate anesthesia. Patients will then undergo randomization for the order
in which they will receive three sequential treatments: etomidate + ECT, ketamine +
ECT, and ketamine + sham ECT. Sessions will be repeated in the same sequence for
a total of six treatments. Before each session, sensorimotor speed, working memory,
and executive function will be assessed through a standardized cognitive test battery.
After each treatment, the return of purposeful responsiveness to verbal command will
be determined. At this point, serial cognitive assessments will begin using the same
standardized test battery. The presence of delirium and changes in depression severity
will also be ascertained. Sixty-four channel EEG will be acquired throughout baseline,
ictal, and postictal epochs. Mixed-effectsmodels will correlate the trajectories of cognitive
recovery, clinical outcomes, and EEG metrics over time. This innovative research design
will answer whether: (1) time to return of responsiveness will be prolonged with ketamine
+ ECT compared with ketamine + sham ECT; (2) time of restoration to baseline function
in each cognitive domain will take longer after ketamine + ECT than after ketamine
+ sham ECT; (3) postictal delirium is associated with delayed restoration of baseline
function in all cognitive domains; and (4) the sequence of reconstitution of cognitive
domains following the three treatments in this study is similar to that occurring after an
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isoflurane general anesthetic (NCT01911195). Sub-studies will assess the relationships
of cognitive recovery to the EEG preceding, concurrent, and following individual ECT
sessions. Overall, this study will lead the development of biomarkers for tailoring the
cogno-affective recovery of patients undergoing ECT.
Keywords: electroconvulsive therapy, electroencephalography, major depressive disorder, ketamine, anesthesia,
seizures, neurocognitive disorders, consciousness
INTRODUCTION
Seizures—Unique States for Probing the
Return Consciousness and Cognition
The return of consciousness following reversible states of
unresponsiveness is relevant to neuroscience and clinical
practice. Neural mechanisms underlying these processes
appear to be distinct, with implications for anesthetic practice
(1) and sleep/wake disorders (2). While states incurred by
general anesthesia (3–5) and sleep (6, 7) have suggested
neural substrates necessary for sustaining consciousness (8),
the recovery from these depressed states of neural activity
remains poorly characterized. Comparatively less is known
regarding the recovery from states of highly synchronized
neural activity incurred through generalized seizures (9, 10).
Characterizing the recovery of neural activity and cognitive
function following these states may provide a system to
complement states of brain suppression given that: (1)
action potential synchronization is a fundamental mode of
information processing in the cerebral cortex distinct from
neuronal firing rates and (2) seizures arise from changes in the
excitatory and inhibitory synaptic balance in different brain
regions.
The relationships of underlying electroencephalographic
(EEG) activity and the recovery from generalized seizures
is currently limited and challenging to investigate (11).
Generalized seizures are characterized by the loss of
consciousness coincident with ictal EEG spike-and-wave
complexes, polyspike-and-wave complexes, and spikes (12).
External phenotypes, ranging from convulsions to immobile
staring, likely depend on the precise disruption in sub-
cortical arousal systems, cortical-subcortical interactions,
or neocortical connectivity (9, 10, 13). Inter-individual
heterogeneity among clinical seizures may arise from diverse
structural or metabolic derangements. Moreover, seizures are
typically sporadic, unpredictable in occurrence, and may vary
in intensity and character, making them difficult to study
systematically. Following the disappearance of epileptiform
EEG signatures, the postictal period begins and culminates
in a return of consciousness and cognitive function. There
is little standardization of postictal clinical and behavioral
testing to facilitate objective comparison to EEG changes
during the postictal period. Critical barriers to generating
inferences from reproducible seizures may be addressed in
the context of electroconvulsive therapy (ECT) (14), where
seizures are electrically induced under safely controlled
conditions.
EEG Activity and Cognitive Dysfunction
Following ECT
The potential of EEG to inform clinicians on the future efficacy
and side effects of ECT has not been fully realized. EEG
is commonly monitored during ECT, a proven treatment for
depression, bipolar illness, and psychosis (15). Following the
delivery of the ECT stimulus charge, epileptiform activity in the
bilateral fronto-mastoid EEG can complement the assessment of
peripheral tonic-clonic muscle activity (16). Clinically relevant
EEG measures beyond the length of seizure duration (17) have
unclear clinical utility (18). Optimally, EEG markers would be
available for predicting and refining ECT administration to
balance efficacy and side effects that accrue over the course of
therapy. EEG measurements acquired on the day of treatment
would inform clinicians prior to stimulus delivery. The spatial,
temporal, and spectral properties of such markers remain
unknown. Once ascertained, translation to clinical practice
would require a sparse montage of EEG sensors that can
generalize across patient gender, age, and recovery from general
anesthesia. Similar advances in the field have not occurred
since prior work establishing a relationship between cognitive
performance and ECT stimulation parameters (19, 20). This void
may be due to the paucity of studies that have characterized
EEG across widely distributed brain regions using either 10–20
montages (21–24) or high-density EEG. The spatial resolution
offered by high-density EEG is likely needed to associate
cognitive and affective perturbations to specific EEG patterns.
High-density scalp EEG has shown superiority over standard 10–
20 montage recordings in guiding surgical treatment for epileptic
seizures (25). Extension of this paradigm to the ECT setting may
yield clinically relevant EEGmarkers for tailoring treatment at an
individual patient level.
During the ictal period, seemingly stereotyped EEG patterns
develop and resolve (26), with proposed phases of activity (21).
Brief periods of EEG suppression or rhythmic bilateral 14-22Hz
oscillations may first emerge (21). Induction of bilateral poly-
spike activity occurs, often with greater power on the side of
the stimulation electrode in unilateral ECT (21, 27). Spike/spike-
and-wave complexes then arise, followed by termination within
3min (21, 26). This ictal activity may be followed by postictal
generalized EEG suppression, a marker associated with ECT
therapeutic efficacy (17, 28, 29) and with potential implications
for understanding sudden unexpected death in epilepsy (30, 31).
Delta waves (<4Hz) (26) emerge that are gradually replaced by
theta (4–8Hz), alpha (8–13Hz), and beta (13–30Hz) rhythms
(26). The dynamics of these EEG changes may aid in our
understanding of seizures in general and help to reveal the
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efficacy/side effects of ECT in the postictal period following
future large-scale investigations.
The continued resolution of postictal EEG changes may also
correlate with the cognitive impairments incurred immediately
after individual sessions and progress over the course of ECT
treatments. Perturbations in processed EEG measures persist
even when individuals appear to be awake in the postictal
period (32–34). Patients with greater suppression in processed
EEG measures following ECT are more likely to experience
prolonged memory impairment (35). Specific EEG markers that
can be linked to both underlying neurobiology and cognitive
function have not been developed for the acute period after
ECT. Beyond individual sessions, persistent slow theta and
delta oscillations have been observed in the EEG (36) and may
resolve only weeks following the last session (37, 38). These
markers that remain weeks after ECT sessions may be linked
to either therapeutic efficacy (38) or the extent of disorientation
and retrograde amnesia (39). Definitive relationships remain
speculative.
The recovery of cognitive function following individual ECT
sessions has not been fully characterized. Recent analyses have
shed light on the incidence and persistence of cognitive side
effects related to this procedure (40). Approximately 5–12%
of patients experience postictal agitation and disorientation
after ECT (41, 42) that may last 1–2 h after ECT. Postictal
agitation does not occur reproducibly in the same patients
following subsequent treatments (43). Disorientation during
the early postictal recovery from ECT appears to decrease
with number of sessions (44). In contrast, interictal confusion
accumulates with successive ECT sessions (44). Cognitive side
effects may persist for 90min following seizure termination (45).
The temporal development and progression over the course of
ECT remain unclear, but deficits in verbal memory, executive
function (46), and visuospatial memory (47) have been identified.
Cognitive impairments during the course of ECT can delay
treatment (48), contribute to missed work, burden caregivers.
Given that each session of ECT requires the administration
of general anesthesia during seizure induction, systematic
study requires accounting for these potent neuromodulatory
agents.
Control for Anesthetic Exposure
Elucidating cognitive recovery following seizures in the context
of ECT requires a control to account for the effects of general
anesthesia. This is because modern ECT is conducted under
general anesthesia and pharmacologic neuromuscular paralysis.
Anesthetics with mechanisms invoking γ-aminobutyric acid
(GABA) A-type receptor agonism (e.g., etomidate) or NMDA-
receptor antagonism (ketamine) are commonly used. Ketamine
has received greater attention recently since subanesthetic doses
of ketamine have shown efficacy in treating refractory depression
(49–52). Relative to other anesthetics in use for ECT, ketamine
may provide faster recovery from cognitive impairment on
the day of treatment (53, 54) or offer additive benefits on
ECT efficacy (54). Thus, ketamine may be useful in a sham
ECT condition to control for anesthetic exposure while offering
potential therapeutic effects even in the absence of electrical
stimulation.
Hypotheses and Aims
This is a randomized crossover trial to investigate the
recovery of cognitive and neurophysiological function following
right-unilateral ECT in individuals with treatment-resistant
depression. We hypothesize that the reconstitution among
different cognitive domains will markedly vary in rate and order,
depending on the presence of seizures induced by electrical brain
stimulation. Our specific aims include: (1) assess whether the
time to return of responsiveness will be prolonged with ketamine
+ ECT compared with ketamine + sham ECT; (2) ascertain
whether the time of restoration to baseline function in each
cognitive domain will take longer after ketamine + ECT than
after ketamine + sham ECT; (3) determine if postictal delirium
is associated with delayed restoration of baseline function in
all cognitive domains; and (4) determine whether the sequence
of reconstitution across cognitive domains is similar to that
occurring after an isoflurane general anesthetic; we also anticipate
these cognitive disturbances to mirror recovery in EEG power
spectral measures, despite substantial variability across our
sample.
METHODS AND ANALYSIS
This protocol includes elements elaborated in the Standard
Protocol Items: Recommendations for Interventional Trials
(SPIRIT) checklist (55, 56).
Participants
Ethics Approval
The HRPO at Washington University School in St. Louis has
approved the study. The study will be conducted with strict
adherence to Washington University Institutional Review Board
protocol. American Board of Anesthesiology board-certified
anesthesiologists with experience in conducting clinical studies
will lead the study. Safety and privacy of study participants will be
safeguarded in compliance with the Health Insurance Portability
and Accountability Act.
Inclusion and Exclusion Criteria
Inclusion criteria include: (1) Referral for ECT via right
unilateral stimulation for treatment-resistant non-psychotic
unipolar depression or bipolar disorder, (2) Fluency in English,
(3) Age greater than 18 years, and (4) Ability to provide
written informed consent. Exclusion criteria are: (1) Known
brain lesions or neurological illness with sufficient cognitive
impairment to prevent cognitive testing prior to ECT initiation,
(2) Schizophrenia, (3) Schizoaffective disorder, (4) Blindness
or deafness that may impair performance on cognitive testing,
or (5) Inadequate seizure duration with etomidate general
anesthesia, defined at our institution as bilateral spike-and-wave
complexes present for less than 10 s. Past suicidality or substance
use disorder will not exclude patients from enrollment.
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Design and Procedure
Recruitment
Given the sample size used in our prior study (57), 15 patients
will be recruited over a span of three years. Psychiatrists will
brief prospective patients on the study to determine eligibility
and interest. Trained study team members will formally screen
and enroll interested patients during a preoperative clinic visit
or in the hospital ward. All enrolled patients will provide written
informed consent, with adherence to the Declaration of Helsinki.
Patients will not be charged for participating and will receive
remuneration of $100 per completed treatment session, up to
$600.
Interventions
Each patient will be scheduled for an initial dose-charge titration
and six treatment sessions over the initial 2 weeks of the ECT
treatment cycle (Figure 1) at Barnes-Jewish Hospital, St. Louis,
MO, USA. Patients will receive three sequential treatments:
etomidate + ECT, ketamine + ECT, and ketamine + sham
ECT. These treatments will be repeated in the same sequence
over the subsequent week. The study focuses on changes in
in cognoaffective function over the initial period of the ECT
index course prior to maintenance therapy. A 2-week duration of
involvement was chosen to maximize patient tolerance of study
procedures and minimize repetition of stimuli.
Randomization and Blinding
A trained team member will use a computer-generated
randomization algorithm among 18 potential combinations of
initial cognitive task and order of study interventions. Random
assignments will account for investigator-physician availability
for ketamine + sham ECT sessions. The patient will be blind
to the order of treatment condition. Study and clinician teams
will be aware of the treatment arm at each session and maintain
routine checks and monitoring before and after anesthetic
induction. In order to maximize adherence to the intervention
protocol, a study coordinator will inform research and clinical
teams of the treatment condition prior to the study session day,
and brief these teams on study procedures immediately before
the subject’s scheduled treatment session. To maintain sufficient
blinding of the subject to the treatment condition, patients will
not be able to view the syringe during anesthetic induction during
any treatment session. Furthermore, stimulation electrode and
conducting gel will also be placed on the scalp following loss
and prior to return of responsiveness during sham-ECT sessions.
Post-anesthetic evaluation by anesthesiology, psychiatry, and
nursing staff will be consistent across sessions.
To maximize study rigor and reproducibility, investigators
evaluating studymeasurements for data quality and development
of analytical tools will be blinded to the details of the treatment
intervention, whenever possible (58).
Timeline of Treatment Visits
Dose-Charge Titration
As part of standard care, the patient will be admitted for an
initial dose-charge titration to induce a generalized seizure of
adequate duration under etomidate general anesthesia. This
session will serve to determine the seizure threshold and
tolerance for the study procedures (Figure 2A). During this
visit, the study team will assess baseline cognitive function
and EEG prior to ECT, tolerability of cognitive testing and
EEG recording, and feasibility of etomidate as the anesthetic
for study and subsequent treatments. ECT charge will be
delivered via a Thymatron System IV (Somatics, LLC, Venice, FL,
USA). Per ECT laboratory procedures, stimulation parameters
include a current of 0.9 amperes, pulse width of 0.3ms, with
escalating dosage: (5% total charge: 24.9 millicoulombs, 10Hz
stimulation, 4.6 s duration; 10% total charge: 50.8 millicoulombs,
FIGURE 1 | Overall study design. Patients are randomized to repeated testing on three different treatment (Tx) interventions: Etomidate + ECT (E + ECT), ketamine +
ECT (K + ECT), and ketamine + sham ECT (K + Sham). These interventions occur over a 2-week period following a dose-charge titration session that determines the
adequate ECT charge for treatment-resistant depression.
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FIGURE 2 | Timelines for dose-charge titration and treatment sessions. (A) Baseline cognitive assessments are acquired before the dose-charge titration session with
etomidate general anesthesia. (B) Baseline cognitive assessments are acquired before each treatment session and serially from the return of responsiveness to verbal
command (T = 0) and up to 90min afterwards (T = 90). Continuous high-density EEG is acquired during baseline assessments and treatment sessions.
20Hz stimulation, 4.65 s duration, 15% total charge: 75.6
millicoulombs, 20Hz stimulation, 6.98 s duration). Subsequent
planned ECT treatment is based on a six-fold increase in charge
delivery. Thus, individuals without suitable seizure duration at
a projected 100% charge will be withdrawn from the study if
subsequently scheduled for bilateral ECT. Participants will not be
withdrawn if their standard-of-care anesthetic is changed from
etomidate to another anesthetic, such as ketamine.
Study Intervention Treatment Sessions 1–6
Following randomization, each patient will initiate a complete
course of therapy with participation in six treatment sessions
(Figure 2B). During four of these six sessions, the patients will
receive care within standard practice for ECT: general anesthesia
(etomidate or ketamine), muscle paralysis (succinylcholine), and
electrical stimulation. For the remaining two sessions, patients
will undergo a ketamine general anesthetic without muscle
paralysis or ECT stimulation.
High-density EEG, bilateral fronto-mastoid clinical EEG, and
full American Society of Anesthesiologists (ASA) monitoring
will commence prior to the induction of general anesthesia.
Additionally, audible squeeze toys will be placed in each hand
of the patient, who will be instructed to follow serial commands
to either “Squeeze your left hand twice” or “Squeeze your
right hand twice.” Every 30 s, one of these recorded audio
commands will be played at random, to monitor loss and
return of responsiveness to verbal command. Patients will be
pre-oxygenated by mask and anesthesia will be induced with
ketamine, approximately 2 mg/kg, or etomidate, approximately
0.2 mg/kg. Following bolus of the induction agent, loss of
responsiveness and eyelash reflex will be confirmed. Loss of
responsiveness to verbal command will be recorded as the first
time when a subject fails to correctly respond to the standardized
auditory commands. Care adherent to the ASA guidelines will be
performed regardless of treatment session. For sessions with ECT,
pre-stimulation hyperventilation and assisted ventilation will
also be performed. Central seizure duration will be assessed from
bilateral fronto-mastoid EEG by the psychiatry team. Peripheral
seizure duration will be determined throughmonitoring of tonic-
clonic activity (16). During all sessions other drugs will also
be administered according to current practice and as clinically
indicated (e.g. for nausea or headache).
During the recovery from the study intervention, the study
team will note spontaneous eye opening and compliance to
commands to ascertain the timing for return of responsiveness.
The ability to extend the thumb to verbal command (“thumbs
up”) will be assayed every 30 s. Timing for opening of eyes
to command will be noted. These requests will be preceded
with the patient’s name to increase emotional valence. Return
of responsiveness will be defined as the first time at which
the patient squeezes the correct hand precisely as instructed
via the standardized auditory commands. At this time, defined
as t = 0min, the subject will begin a series of cognitive and
behavioral assessments, which are repeated every 30min up to
90min after return of responsiveness. Patients will be permitted
to take brief breaks to use the restroom and eat or drink, as
necessary. They will be discharged according to standard post-
anesthesia care unit discharge criteria upon completing the last
neurocognitive test battery. A study site coordinator will contact
each subject within 24 h of the study day to assess and document
any adverse events, as well as confirm the subject’s continued
involvement in the study.
DATA COLLECTION
The overall design of data collection for the dose-charge titration
session and the experimental treatment sessions differ in the
emergence period after ECT or sham ECT (Figure 2). Primary
study measurements and outcomes are listed in Table 1. Patient
demographics and clinical measures will be maintained using the
Research Electronic Data Capture (REDCap) application (59).
Primary and Secondary Outcomes
Primary outcomes include: the temporal recovery profiles for
cognitive task performance, as measured using the Cognition
assessment battery (60); times for the return of responsiveness
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TABLE 1 | Summary of study measurements and outcomes for primary analyses.
Type Measure/Outcome Purpose
Responsiveness Spontaneous eye opening Spontaneous return of
arousal





Probe with visual cues





Motor Praxis Test Sensorimotor speed
Psychomotor Vigilance Test Reaction time
Digit Symbol Substitution Visual scanning
Fractal-2-Back Working memory
Visual Object Learning Test Memory for complex shapes
Abstract Matching Test Executive function
Clinical Outcomes Scale of Suicidal Ideation Suicidal Ideation
PROMIS-CAT Depression:
Computer-based
Self-Assessment Manikin Depression: Visual-analog
3D-CAM Delirium Assessment
QIDS-SR16 Depression: Self-report
Seizure Markers Frequency Rate of ictal complexes









Alpha Band (8–13Hz) Spectral content
Beta Band (13–30Hz)
Gamma Band (30–70Hz)
to auditory command; and the presence of delirium, evaluated
through the 3-minute Diagnostic Assessment for CAM-defined
delirium (3D-CAM) (61).
Secondary outcome measures based on the EEG will
include characterization of the seizures by both expert reader
interpretation and quantitative techniques (62). Central seizure
duration will be visually determined by clinician evaluation of
the frontal-mastoid bipolar EEG ictal complexes. Additional
measures will be calculated from windowed analyses of the
high-density EEG: power spectral measures of the interval
between anesthetic induction to delivery of ECT stimulus
charge; the seizure envelope for 1–12Hz EEG power; peak-to-
peak amplitude, calculated from the difference in maximum
and minimum voltages within 200ms time; periodicity of
epileptiform discharges; inter-hemispheric symmetry of seizure
discharges; intra- and inter-hemispheric coherence. When
possible, these measures and power spectral estimates will be
derived from different phases of the ictal waveforms (27). The
following postictal EEG measures will be assessed: duration
and signal amplitude of postictal EEG suppression; power
spectral parameters flanking the return of responsiveness to
verbal command; and power spectral parameters from eyes
open and closed epochs, including assessments of the posterior
dominant rhythm. Spatiotemporal analyses will also focus on the
propagation of EEG signatures during the ictal and early postictal
period.
Additional secondary outcomes include: suicidality, mood,
depression severity, delirium, and treatment course outcome.
Cognition Test Battery
Cognitive assessments will be administered on a Dell
Latitude E5430 Laptop with a 14-inch liquid crystal display
(Round Rock, TX, USA) using Cognition test battery software
(60). Cognition consists of 10 brief neuropsychological tests
with known cerebral representation that cover a wide range
of cognitive domains (60). Patients will watch a standardized
instructional video for baseline testing prior to the dose-
charge titration session. Additional pre-intervention baseline
assessments will also be performed on each treatment session
prior to induction of general anesthesia. Post-treatment testing
will occur at return of responsiveness to auditory command
(t = 0) and at t = 30, 60, and 90min. Each testing bout will take
approximately 15–20min to complete wherein the first cognitive
test will be repeated as the last test at each time point. The order
in which the tests are administered will be randomized between
subjects but will be held constant across treatment sessions for
a given patient. These tests have been previously employed in
probing cognitive function during the recovery from isoflurane
general anesthesia (57).
Motor Praxis Test (MPT)
This test assesses sensorimotor speed (63). Participants use a
touchpad to click on squares that appear at random locations
on the screen. The difficulty of tracking increases as successive
squares become smaller.
Psychomotor Vigilance Test (PVT)
The PVT evaluates reaction time for detecting visual stimuli at
random inter-stimulus intervals (64). During this 3-min test,
subjects are instructed to monitor for a counter on the screen
and to hit the space bar as quickly as possible once the counter
appears.
Digit Symbol Substitution Test (DSST)
This test assesses memory, complex scanning, and visual tracking
based on a paradigm used in the Wechsler Adult Intelligence
Scale (65). Subjects are presented with a legend that pairs unique
symbols to digits (1 through 9). Symbols are then sequentially
presented on the screen in random order over a 90 s testing
period. Participants are instructed to press the corresponding
number key as soon as possible.
Fractal-2-Back (F2B)
As a variant of the Letter 2-Back task (66), the F2B assesses
working memory through sequential presentation of fractal
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patterns that fill the screen. During the testing bout, each pattern
may have multiple presentations. Subjects are asked to press
the space bar when the current stimulus matches the pattern
displayed two fractals previously.
Visual Object Learning Test (VOLT)
Memory for complex visual figures is evaluated by the VOLT
(67). Ten complex three-dimensional figures are presented on the
screen for participants to memorize. Participants are then asked
to select these ten objects from a set that also contains ten decoys,
with each of the 20 objects presented individually in random
order.
Abstract Matching Test (AMT)
This test assesses components of executive function, including
the development of implicit abstract rules (68). During the AMT,
two pairs of objects are shown, one at the bottom left, and one at
the bottom right of the screen. A target object appearing in the
middle of the screen must be classified as fitting better with one
of the two groups based on shape or fill pattern.
MPT, PVT, and DSST use stimuli that are randomly generated
prior to each test administration. For F2B, VOLT, and AMT, 15
unique versions exist, and up to 14 versions will be used for this
protocol. The same stimuli will be repeated after the 14 versions
of these tests have been exhausted. Due to the number of stimuli
and the time between ECT sessions, it is unlikely that subjects
will remember specific stimulus sequences or stimuli across ECT
sessions.
Median reaction time and accuracy will be computed for
each of the multiple testing bouts within each session, including
pre-treatment baseline and during recovery. For each treatment
session, parameters obtained after the return of responsiveness
to verbal command will be subtracted from baseline to arrive
at repeated measures that account for the recovery in task
performance over time.
Suicidal Ideation, Depression Severity, and
Delirium Assessment
At the beginning of each study session, the first two questions
of the Scale of Suicidal Ideation (69) will be used to assess the
patient’s subjective desire to hurt him- or herself. These two
questions, “Wish to live?” and “Wish to die?”, have been used
previously for assessing changes in suicidal ideation before and
after a brief ketamine infusion for major depressive disorder (70).
Depression severity will be assessed using the Patient-
Reported Outcomes Measures Information System-Computer
Adaptive Testing (PROMIS R©-CAT) survey for depression.Mood
will be quantified via the Self-Assessment Manikin (SAM,
Supplementary Material 1) (71), a brief scale appropriate for
patients with transient cognitive impairment following ECT.
Baseline assessments will be performed prior to the dose-
charge titration. To determination improvement on the day
of treatment, the PROMIS R©-CAT and the SAM will be
administered prior to anesthetic induction on all study sessions
and after the last cognitive battery of each treatment session. As
part of standard care for tracking depression symptoms during an
ECT course, treating psychiatry teams will administer the Quick
Inventory of Depressive Symptomatology, Self-Report (16-Item),
QIDS-SR16 (72).
Delirium will be assessed with the 3-min Diagnostic
Assessment for CAM-defined delirium (3D-CAM) (61). The 3D-
CAM will be administered at baseline, prior to the dose-charge
titration visit, prior to each treatment visit, and post-treatment
at t = 0, and 60. However, if the patient is negative for the 3D-
CAM assessment at any time during the recovery, subsequent
assessments will not be performed during the remainder of the
session.
To assess quality of treatment blinding, the patient will be
asked their impression of whether they received ECT at the last
testing point on each treatment session. The patient will be asked,
“Do you feel that you received ECT today? Was ECT painful?”
EEG and Video Acquisition
EEG will be collected during the dose-charge titration session
and during all treatment sessions to assess pre-ECT and pre-
anesthetic baseline EEG recordings. An appropriately fitted
64-channel EEG Geodesics Sensor Net (Electrical Geodesics,
Inc. Eugene, OR, USA) will be affixed to the scalp and
face. Elefix electrode paste (Nihon Kohden America, Inc.,
Irvine, CA, USA) will be injected to maintain conductivity
to the silver/silver-chloride electrodes. Electrode impedances
on each channel will be optimized to be less than 100
kOhms/channel, per manufacturer’s suggestions. EEG signals
(500Hz sampling rate) will be acquired with a Net Amps 400
amplifier and Net Station version 5.0 and above (Electrical
Geodesics, Inc. Eugene, OR, USA) via a Late 2012 Mac
Pro Workstation (Apple Cupertino, CA, USA). Whenever
possible, video synchronized to EEG will be acquired using an
Axis P3364LV network camera (Axis Communications, Lund,
Sweden).
EEG Preprocessing and Analysis
Netstation Tools and EEGLab will be used to assess for quality
and to reduce artifact related to motion and eye movements
(73). Bad channels will be identified by visual inspection. Signals
will be filtered from 1 to 100Hz and subsequently downsampled
to 250Hz. Modules of the PREP pipeline (74) will be used to
reduce artifact related to line noise and movement. Reduction
of eye movement artifacts will employ independent component
analysis. For ictal recordings, preprocessing will be tailored to
minimize distortion of seizure complexes. The following analysis
time epochs will be evaluated for secondary outcomes related to
EEG activity: pre-ECT and post-ECT periods with either eyes
open or eyes closed, the interval between anesthetic induction
and ECT stimulation, the period between stimulus delivery
and cessation of ictal waveforms/spike-and-wave complexes,
postictal period of EEG suppression and slowing, and both
5-min epochs flanking the return of responsiveness to verbal
command.
Spectral analysis will be performed using the Chronux
Toolbox (75), including five tapers, time frequency bandwidth of
3, and 6-s non-overlapping time windows. Total power and peak
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amplitude will be computed within the delta (1–4Hz), theta (4–
8Hz), alpha (8–13Hz), and beta (13–30Hz) bands. Sub-studies
will focus on coherence and phase lag indices, as computed using
the Chronux toolbox. Global coherence (76) and permutation
entropy will also be computed (77).
In parallel to power spectral analyses, we will track the
time-varying connectivity between the measured brain regions.
Data will be windowed into 5–10 s epochs within which
several cross-channel connectivity metrics will be computed.
These measures will include the Pearson correlation, directed
entropy, and Shannon mutual information. Thus, windows will
manifest different “networks,” each describing the association
between channels (regions) according to its respective metric.
These networks will be clustered into a set of distinct
motifs, or microstates, by using a k-means algorithm with
least-squares error criterion. Other methods to characterize
the time-varying dynamics of the observed brain activity,
including those based on network control theory, will also be
considered.
Visualization and analyses of epileptiform EEG activity will
be performed using Net Station and Persyst software (Persyst,
Solana Beach, CA, USA), following interpolation of bad channels
and re-referencing to the average signal. EEG dipole localization,
inter-hemispheric generalization, and phase-reversals will be
assessed by epilepsy board-certified neurologists. Seizures will
be staged according to the previously described phases that
follow ECT stimulation (phase I with initial 14–22Hz rhythmic
beta activity, phase II with arrhythmic polyspike activity, and
phase III with rhythmic 2.5–3.5Hz. spike/polyspike activity
(27)). The duration and amplitude of post-ictal generalized
EEG suppression (PGES) will also be determined. Additionally,
expanding on previous analyses of stationarity in epileptiform
activity induced by ECT (24), we will use high-density
EEG to topographically map rhythmic sharp-wave discharges.
To maintain rigor, evaluators will be blinded to the study
intervention. Quantitative metrics will be derived from spectral
and time-based analyses of the ictal EEG. These measures will
evaluate seizure energy, periodicity, and symmetry, as well as
propagation, and termination.
Sample Size
We based our targeted enrollment on safety consideration for a
ketamine general anesthetic, expected differences in the recovery
patterns of different domains assessed by the Cognition test
battery, and prior volunteer data with isoflurane emergence
(57). Sample size calculations were based on 1-way pairwise of
ANOVA (Analysis of Variance) comparisons of 5 means (t = 0,
30, 60, 90, and 120min). Expected effect sizes for differences in
the modeled trajectories of cognitive function ranged from 20
to 40min. Standard deviations were expected to range between
20 and 40min. Using conservative assumptions, we calculated a
sample size of 24 subjects (effect size, µA-µB, of 20min; standard
deviation, σ, of 20min; two-sided alpha of 0.05; power of 80%).
With liberal assumptions, we estimated a sample size of 12
participants (µA-µB of 40min; σ of 20min; two-sided alpha of
0.05; power of 99%). With this range of estimates and expected
attrition of participants, we targeted for data collection from 15
to 20 participants.
Statistical Analyses
We will employ mixed-effects models to quantify trajectories
of cognitive recovery over time while addressing inter-subject
variance and missing data. Linear models with appropriate
transformations will be used preferentially over non-linear
models. Time and treatment intervention group will be included
as fixed effects while random effects will account for repeated
measures provided by each participant. Day of treatment relative
to the dose-charge titration session will allow consideration
of cumulative effects of treatment order that may remain
biased despite randomization. To address differences in ECT-
stimulation responsiveness, regression approaches will account
for dose charge, central seizure duration, and age. Models will
assess for the effects of treatment on the timing for the return of
responsiveness to verbal command and the presence of delirium.
Separate mixed-effects models will be generated to assess task
performance in a group of young healthy volunteers during the
recovery from isoflurane general anesthesia (57). For example,
the following damped-exponential equations will be used for
mixed-effects models of cognitive task performance over time t,
for an individual k.
Reaction Time (t, k) = 81(t, k)−82(t, k)× exp(−83(t, k))(1)
Accuracy (t, k) = 81(t, k)+82(t, k)× exp(−83(t, k))(2)
Where parameters 81(t,k), 82(t,k), 83(t,k) are optimized at an
individual and group level based on changes in these measures
relative to pre-intervention baseline within a treatment session.
A change in performance at time 0 (return of responsiveness)
would be accounted by 81(k), the asymptotic value on recovery
by82(t,k), and the rate of recovery modeled by83.
Primary Pre-specified Analyses
Recovery of Responsiveness
Given that the induction of generalized seizures by electrical
stimulationmay compound the recovery from general anesthesia,
we expect that interval from loss to return of responsiveness
following ketamine+ ECT will be longer compared to the period
for ketamine + sham ECT. We will determine the median and
95% confidence intervals for this measure in relation to the
treatment intervention.
Recovery of Cognition
Given that postictal suppressionmay be prolonged with ketamine
than with etomidate (78), we hypothesize that the time needed
for the return of cognition to baseline on individual sessions
will be greatest for ketamine + ECT, followed by etomidate +
ECT, and ketamine + sham ECT. Separate mixed-effects models
will be generated based on reaction time and accuracy. We will
determine the time of convergence for 95% confidence intervals
for the marginal responses related to the three treatment groups.
To determine the timing for the recovery to baseline, we will
determine the time when the same 95% confidence intervals
include 0.
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Postictal Delirium and Cognitive Recovery
We expect the incidence of delirium (3D-CAM) to be associated
with delayed restoration of baseline function in all cognitive
domains. Themagnitude and significance of this relationship will
be determined from the mixed-effects models for each cognitive
test.
Comparison of Cognitive Recovery After ECT and
Isoflurane General Anesthesia
We hypothesize that the time for recovery to baseline will be
quicker for treatments involving ECT compared to that for the
recovery from isoflurane general anesthesia. Convergence for




Principal measures of performance are based on preliminary
data (60) of the Cognition test battery. Additional measures
include: PVT response speed, DSST throughput, PVT lapses,
VOLT duration and accuracy, AM duration and accuracy, and
DSST errors. Cognition performance measures associated with
lower effect sizes will also be assessed. These include AM
accuracy, VOLT accuracy, F2B reaction time, MPT accuracy,
MPT duration, and F2B accuracy. Overall, we expect F2B,
VOLT, and AMT to recover the slowest due to taxing of short-
term memory after ketamine + ECT compared to ketamine +
sham ECT.
Recovery in the Spontaneous EEG
We will evaluate mixed-effects models to test the hypotheses that
the predominance of frontal delta or theta power during passive
eyes opening or occipital alpha power during eyes closure predict
cognitive performance (Cognition scores) or delirium (3D-CAM
scores).We will also compare these EEG spectral measures across
treatment sessions to evaluate the impact of anesthetic and ECT.
Relationship of ECT Seizure Duration to Return of
Responsiveness to Verbal Command
We expect that the length of ECT-induced seizures will correlate
with the intervals from the loss of responsiveness to the return of
responsiveness.
Mood and Depression Severity
We expect improvement in these clinical outcomes to be greatest
with ketamine + ECT, followed by etomidate + ECT, and then
ketamine+ sham ECT.
Treatment Satisfaction
We expect satisfaction to be greatest for ketamine + ECT,
followed by ketamine + sham ECT, and then by etomidate
+ ECT.
RISKS AND JUSTIFICATION
Candidates for ECT are refractory tomultiplemedical modalities.
These patients may benefit from a greater understanding of the
impact of anesthetics and ECT on the severity of the underlying
psychiatric illness and the recovery of cognitive function.
Ketamine may improve the efficacy of ECT and recovery of
cognitive function following ECT. Patients may benefit from
the additional EEG monitoring in the postictal period during
which non-convulsive status epilepticus is rarely manifested.
Risks from exposure to ketamine include self-limited tachycardia,
hypertension, hallucinations, agitation, and delusions.
RESEARCH CONDUCT
Treatment sessions will be conducted at Washington University
School of Medicine under the general supervision of a board-
certified anesthesiologist who is familiar with post-anesthetic
and post-intervention care. Patients will be monitored during
emergence and recovery from anesthesia by the anesthetic and
nursing staff in the ECT suite as per standard care. Additionally,
research personnel trained in good clinical practices will be
present during the acquisition of data. Monitoring and safety
will be according to the current clinical standard. Patient
confidentiality will be maintained through de-identification of
personal health information. Identity and linking information
will be stored in a locked cabinet within the principal
investigator’s office, which is locked outside of business hours.
Electronic data will be password-encrypted on secure servers.
Patient satisfaction will be monitored throughout the
study (Supplementary Material 2). Discontinuation of study
procedures will be proposed if withdrawal is in the best interest
of the patient or if removal of treatment blinding is requested.
In the event that different interventions are needed from
those allocated, the patient will be withdrawn from the study.
Participants will be given a satisfaction survey to be returned by
mail following the last study session (79).
ADVERSE EVENTS AND PREMATURE
DISCONTINUATION
The Washington University in St. Louis Human Research
Protection Office (HRPO) and the Data and Safety Monitoring
Committee (DSMC) will oversee the study’s progression and
adherence to protocol. The study was approved by HRPO on
March 24, 2016. Following each intervention, the principal
investigators will affirm continued involvement or withdrawal
based on patient tolerance and data quality. All adverse events
will be reviewed by the DSMC and reported to HRPO, following
the reporting policies and procedures, and followed until
satisfactory resolution. The description of the adverse experience
will include the time of onset, duration, intensity, known
etiology, relationship to the study, and any treatment required.
The trial steering committee will be responsible for all major
decisions regarding changes to the protocol. The committee will
communicate these changes to HRPO and appropriate parties.
DISSEMINATION
The final trial dataset will be the property of the investigative
team and shall not be shared without permission from
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the principal investigators. Dissemination plans include
presentations at local, national and international scientific
conferences. Every effort will be made to publish results of this
trial in peer-reviewed journals. Dissemination of results to study
participants and their family members will be available upon
request. Updates and results of the study will be available to the
public at www.clinicaltrials.gov. The trial was first registered
on April 30, 2016 as NCT02761330. The first participant was
enrolled on May 3, 2016.
DISCUSSION
This study will be the first to elaborate the time course and
sequence whereby consciousness, cognition, and EEG activity
recover following seizures induced for ECT. The randomized,
repeated methods design of the study is powerful, as it will
allow several within-patient comparisons. Specifically, the design
will allow us to distinguish between the effect of ketamine
anesthesia alone versus the combined effect of ketamine and
ECT. Recovery of consciousness after etomidate is expected to
be rapid, on the order of minutes. Therefore, the etomidate +
ECT arm should provide an additional comparator condition
to the ketamine + ECT arm. Intra-patient repetition of each
of the three exposures over 2 weeks will help to establish
the reproducible effect of each exposure on the outcomes of
interest.
Past EEG studies during and after ECT show interesting
correlates with clinical outcomes, including degree of increased
post-ECT slowing (theta and delta activity) during the course
of treatment for depression (80). However, EEG acquisition
techniques have varied widely in past studies, with some studies
using limited EEG electrode coverage of the bifrontal regions
(45) and others using more conventional standard clinical
EEG montages (38). Techniques with broad head coverage
and high sensor density, such as magnetoencephalography,
have already shown promise in further characterizing post-
ECT changes such as increases in slow delta and theta
rhythms, and decreases in faster alpha and beta rhythms (81).
The use of high-density EEG in the current study offers
an extension of current clinical monitoring with extensive
electrode coverage over the scalp. This approach may expand
the possibility of detecting meaningful EEG changes that
correlate with post-ECT changes in consciousness and treatment
effects.
Limitations of the study include an inability of our sample
size to account for variability across medical treatment regimens.
Despite our efforts to minimize subjective bias across treatment
arms, patient unblinding is possible due to psychoactive effects of
ketamine that are not associated with etomidate. Furthermore,
the lack of pharmacologic muscle paralysis during sham ECT
treatments may also contribute if muscle aches are encountered
during the study. Without drug levels of ketamine, we will
be unable to rule out the possibility that any prolongation in
depressed cognition or consciousness is related to changes in
hepatic blood flow or function during ECT compared to sham
treatments. Finally, the effects of timing between treatments and
of successive treatments over time may not be fully addressed by
our study design.
The cognitive domains assessed through the study test
battery are components of complex cognoaffective processes
that may be more closely linked to activities of daily living.
Further investigation will be able to address measures that
integrate cognitive domains and emotional valence or account
for cognitive distortions (82). While potentially more difficult
to assess, these meaningful outcomes will yield a greater
understanding of how patients perceive and interact with their
environment.
An underlying motivation for this work is that cognitive
impairments incurred over the ECT index course limit patient
functionality and adherence to this important treatment
modality. Comparisons of task performance before and after an
index course have identified deficits in orientation (83, 84) and
different forms of memory (47, 85–90). Cumulative treatments
of ECT are associated with anterograde (91) and retrograde
amnesia (92), primarily following the entire course regimen (40).
Cognitive deficits resolve within days (40) to weeks after the index
course of therapy (87, 88, 90, 93). The links between these longer-
term deficits and the perturbations incurred over the shorter time
scales of the proposed investigation constitute future avenues of
inquiry.
We anticipate our findings to lay the groundwork for larger
mechanistic studies for generating markers that reflect the
efficacy and side effects of ECT across an array of psychiatric
illnesses. These insights could impact our understanding of other
neuromodulatory therapies. Overall, ECT remains an established
and effective modality for treating refractory mental illness.
Future neural markers for aiding decision-making of patients
and clinicians could demystify ECT, thereby improving access,
adoption, and adherence.
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